UnknownPhase 2

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

France58 participantsStarted 2020-09-10

Plain-language summary

AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains. Subcutaneous tocilizumab, a targeted biotherapy, recently received marketing authorization for the treatment of GCA, but only demonstrated at yet that it can allow steroid dose sparing. The aim of this study is to assess the benefit of tocilizumab and IV steroids combination or IV steroids alone, in the treatment of AION due to GCA.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age of 50 years or older
✓. Social insurance
✓. Diagnosis of AION, characterized by sudden and painless loss of vision, of less than one week, accompanied by pallid swelling of the optic disc
✓. Sudden permanent visual loss due to AION, of less than one week
✓. Diagnosis of GCA based on the 1st (age ≥ 50 years) and the 3rd (Diagnosis of AION) criteria and at least one among the following :

What they're measuring

ocular change

Timeframe: Week 8

Trial details

NCT IDNCT04239196

SponsorCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-09

Contact for this trial

Tania RILCY

+33 140021126 trilcy@15-20.fr

View on ClinicalTrials.gov More Giant Cell Arteritis trials